Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
Type:
Grant
Filed:
October 25, 2011
Date of Patent:
January 21, 2014
Assignee:
Genentech, Inc.
Inventors:
Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.
Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
Type:
Grant
Filed:
May 8, 2012
Date of Patent:
January 21, 2014
Assignee:
Universitätsklinikum Freiburg
Inventors:
Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
Abstract: Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
January 14, 2014
Assignee:
Institute of Virology Slovak Academy of Sciences
Inventors:
Claudiu Supuran, Andrea Scozzafava, Silvia Pastorekova, Jaromir Pastorek
Abstract: The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens, and antibodies directed against the same.
Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.
Type:
Grant
Filed:
January 28, 2011
Date of Patent:
January 14, 2014
Assignee:
Nordic Nanovector AS
Inventors:
Roy H. Larsen, Jostein Dahle, Øyvind S Bruland
Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
January 14, 2014
Assignee:
Galaxy Biotech, LLC
Inventors:
Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
Abstract: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.
Type:
Grant
Filed:
April 27, 2011
Date of Patent:
January 7, 2014
Assignee:
National Research Council of Canada
Inventors:
Abedelnasser Abulrob, Mehdi Arbabi-Ghahroudi, Danica Stanimirovic
Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.
Type:
Grant
Filed:
October 6, 2008
Date of Patent:
January 7, 2014
Assignees:
Kyowa Hakko Kirin Co., Ltd., La Jolla Institute for Allergy and Immunology
Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Inventors:
Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
Abstract: The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.
Type:
Grant
Filed:
August 23, 2010
Date of Patent:
January 7, 2014
Assignee:
Labrys Biologics, Inc.
Inventors:
Ariel Ates Pios, Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller
Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
January 7, 2014
Assignee:
Hanwha Chemical Corporation
Inventors:
Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Dong Eun Lee, Su Yeon Ryu, Hyun Bo Shim, Kyung Jae Kang
Abstract: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.
Type:
Grant
Filed:
November 15, 2006
Date of Patent:
January 7, 2014
Assignees:
Chugai Seiyaku Kabushiki Kaisha, National Hospital Organization, Shinshu University
Abstract: The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a different antigen on a target cell, are required to interact together at the cell surface in order to form an active complex which directs demibody-mediated cellular or complement mediated cytotoxicity and/or reporter function and/or therapeutic activity. The demibodies of the present invention are useful in the targeting of particular cells such as cancer cells including leukemic cells, pathogens including malarial, bacterial and viral agents, and stem cells including embryonic and adult stem cells and pathogen cells. The present invention provides, therefore, methods of treatment, diagnosis and undertaking research and compositions comprising demibodies useful for same.
Type:
Grant
Filed:
November 29, 2006
Date of Patent:
January 7, 2014
Assignee:
The University of Sydney
Inventors:
Richard Ian Christopherson, Jacqueline Mary Matthews, Joel Peter MacKay
Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
January 7, 2014
Assignee:
Morphotek, Inc.
Inventors:
Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
Abstract: The present invention is directed to a cross-reactive antibody that specifically inhibits or blocks mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of such an antibody. Also provided is a pharmaceutical composition comprising such an antibody, or a nucleic acid or vector encoding it. Further provided are methods of use of such compositions in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.
Type:
Grant
Filed:
September 23, 2004
Date of Patent:
January 7, 2014
Assignees:
Technische Universitat Munchen, Amgen Inc.
Inventors:
Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
Type:
Grant
Filed:
May 13, 2010
Date of Patent:
December 31, 2013
Assignee:
Genzyme Corporation
Inventors:
Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders
Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
Type:
Grant
Filed:
August 10, 2010
Date of Patent:
December 31, 2013
Assignee:
Incyte Corporation
Inventors:
Roger T. Coleman, Olga Bandman, Craig G. Wilde
Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
December 31, 2013
Assignee:
Novarts AG
Inventors:
Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
Type:
Grant
Filed:
October 25, 2011
Date of Patent:
December 31, 2013
Assignee:
Genentech, Inc.
Inventors:
Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andy Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
Abstract: To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.
Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
December 31, 2013
Assignee:
Biogen Idec MA Inc.
Inventors:
Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.
Abstract: The invention provides a method for detecting the production of one or more analytes by cells in a sample. The method uses one or more immobilized binding proteins to capture one or more analytes released from cells. The, or each, binding protein is localized at one or more discrete locations on a solid surface within a well. Cells are introduced into the well and cultured under conditions suitable for release of the analyte(s) and for binding of the analyte(s) to the binding protein(s). Restricting the binding protein(s) to one or more discrete locations within the well, rather than coating the entire surface of the well, results in increased sensitivity of the assay.
Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
Type:
Grant
Filed:
June 6, 2012
Date of Patent:
December 24, 2013
Assignee:
Novo Nordisk A/S
Inventors:
Kristian Kjaergaard, Soeren Lund, Soeren Berg Padkjaer
Abstract: A method of inhibiting cellular activation by insulin-like growth factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
Type:
Grant
Filed:
August 26, 2011
Date of Patent:
December 24, 2013
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
Type:
Grant
Filed:
June 12, 2008
Date of Patent:
December 24, 2013
Assignees:
AC Immune S.A., Genentech, Inc.
Inventors:
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
December 24, 2013
Assignee:
Medtronic, Inc.
Inventors:
Lisa Lynn Shafer, Francis Joseph Carr, James Peter Gregson, Dawn Ann Bembridge, Tim Jones
Abstract: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an A?PP epitope spanning the ?-secretase cleavage site of A?PP and a method for inducing an immune response against the ?-secretase cleavage site of A?PP using this immunizing composition. The present invention is also directed to antibodies against the ?-secretase cleavage site of A?PP and their use in a method for inhibiting the formation of amyloid ?.
Abstract: Anti-CD24 antibodies and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are provided.
Type:
Grant
Filed:
November 13, 2008
Date of Patent:
December 24, 2013
Assignee:
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Abstract: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.
Abstract: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.
Abstract: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.
Type:
Grant
Filed:
April 23, 2010
Date of Patent:
December 17, 2013
Assignee:
Theraclone Sciences, Inc.
Inventors:
Po-Ying Chan-Hui, Steven Frey, Andres G. Grandea, III, Thomas C. Cox
Abstract: Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.
Type:
Grant
Filed:
July 16, 2004
Date of Patent:
December 17, 2013
Assignees:
Amgen Inc., Amgen Fremont Inc.
Inventors:
Teresa L. Burgess, Angela Coxon, Larry L. Green, Ke Zhang
Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
Type:
Grant
Filed:
July 29, 2009
Date of Patent:
December 17, 2013
Assignee:
Eli Lilly and Company
Inventors:
Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
Type:
Grant
Filed:
July 8, 2010
Date of Patent:
December 17, 2013
Assignee:
Zymogenetics, Inc.
Inventors:
Stephen R. Jaspers, Scott R. Presnell, Monica Huber
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Grant
Filed:
June 7, 2012
Date of Patent:
December 17, 2013
Assignees:
University of Massachusetts, Medarex, L.L.C.
Inventors:
Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
Abstract: A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.
Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
Type:
Grant
Filed:
April 29, 2010
Date of Patent:
December 3, 2013
Assignees:
Tel Hashomer Medical Research Infrastucture and Services Ltd., Ramot At Tel Aviv University Ltd.
Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.
Type:
Grant
Filed:
April 6, 2010
Date of Patent:
December 3, 2013
Inventors:
Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
December 3, 2013
Assignee:
The Regents of the University of California
Inventors:
James D. Marks, Isin N. Geren, Jianlong Lou
Abstract: The present invention provides a full human anti-TNF-? monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The antibody in the present invention can be used to prepare medicines for the treatment of autoimmune disorders.
Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Type:
Grant
Filed:
April 25, 2013
Date of Patent:
December 3, 2013
Assignee:
Labrys Biologics, Inc.
Inventors:
Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.